论文部分内容阅读
目的：探讨血清可溶性白介素-2受体（SIL-2R）在原发性肝癌（PHC）患者肝动脉栓塞化疗术（transcatheterarterialchemoembolization，TACE）后的临床意义。方法：分别于术后不同时间检测了解15例第1次行TACE术和6例反复行TACE术的PHC患者血清SIL-2R水平。结果：显示第1次行TACE术的PHC患者治疗前血清SIL-2R水平明显高于正常对照（P＜0．01）。经TACE治疗后1周，SIL-2R开始下降，2周时最低（P＜0.01），但4周时又回复至治疗前水平（P＞0．05）；而多次行TACE术的PHC患者经治疗后2周和4周时仍较低（P＜0．01）。结论：提示多次TACE术可提高免疫细胞活性；监测血清SIL-2R水平有助于判断TACE疗效和选择合理的化疗药物剂量，也有助于预后估计。
Objective: To investigate the clinical significance of serum soluble interleukin-2 receptor (SIL-2R) after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PHC). Methods: The levels of serum SIL-2R in 15 patients who underwent TACE for the first time and 6 patients who underwent repeated TACE were detected at different times after operation. RESULTS: The serum SIL-2R levels in PHC patients before the first TACE were significantly higher than those in normal controls (P<0.01). After one week of TACE treatment, SIL-2R began to decline, the lowest at 2 weeks (P<0.01), but returned to the pre-treatment level at 4 weeks (P>0.05); PHC patients undergoing multiple TACE It was still lower at 2 weeks and 4 weeks after treatment (P<0.01). Conclusion: It is suggested that multiple TACE can improve the activity of immune cells; monitoring the serum level of SIL-2R can help to judge the efficacy of TACE and select a reasonable dose of chemotherapeutic drugs, but also help to estimate the prognosis.